Khajehahmadi Zohreh, Nikeghbalian Saman, Roshanaei Ghodratollah, Mohagheghi Sina
Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Arch Iran Med. 2024 Jan 1;27(1):23-29. doi: 10.34172/aim.2024.04.
Epidemiological studies on liver transplant (LT) patients can provide valuable information about the etiology and trends of cirrhosis. The present study aimed to investigate the prevalence and trend of different etiologies and survival rates of LT patients at the Namazi Transplant Center in Shiraz, Iran, between 2001 and 2018.
In this single-center, retrospective cohort study, the demographic and clinical characteristics of 3751 patients who underwent LT and met the study inclusion criteria, including age, gender, blood group, body mass index, model for end-stage liver disease (MELD) score, cause of cirrhosis, and diabetes, were extracted from patients' physical or electronic medical records between 2001 and 2018.
The MELD scores of LT patients with primary sclerosing cholangitis (PSC), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) cirrhosis significantly decreased over the study period (<0.001). Among the LT patients, HBV infection had the highest frequency (21.09%), followed by cryptogenic (17.33%) and PSC (17.22%). The proportion of patients with PSC and NASH (both <0.001) cirrhosis was significantly increased, so that PSC cirrhosis (2016: 19.4%, 2018: 18.8%) surpassed HBV (2016: 18.4%, 2018: 13.5%), autoimmune hepatitis (2016: 11.7%, 2018: 12.7%), and cryptogenic cirrhosis (2016: 16.1%, 2018:14%) as the leading indication for LT from 2016 to the end of the study period. Fortunately, these patients had a better survival rate than other common diseases (HR: 0.53, CI: 0.43‒0.66; <0.001).
The proportion of NASH and PSC cirrhosis significantly increased during the 18 years of study. However, these patients had an improved survival rate. Therefore, health organizations should pay more attention to non-communicable diseases, especially fatty liver disease and cholangitis.
关于肝移植(LT)患者的流行病学研究可为肝硬化的病因和趋势提供有价值的信息。本研究旨在调查2001年至2018年期间伊朗设拉子纳马齐移植中心LT患者不同病因的患病率和趋势以及生存率。
在这项单中心回顾性队列研究中,从2001年至2018年患者的纸质或电子病历中提取了3751例接受LT并符合研究纳入标准的患者的人口统计学和临床特征,包括年龄、性别、血型、体重指数、终末期肝病模型(MELD)评分、肝硬化病因和糖尿病情况。
在研究期间,原发性硬化性胆管炎(PSC)、乙型肝炎病毒(HBV)和非酒精性脂肪性肝炎(NASH)肝硬化的LT患者的MELD评分显著降低(<0.001)。在LT患者中,HBV感染的频率最高(21.09%),其次是隐源性(17.33%)和PSC(17.22%)。PSC和NASH肝硬化患者的比例均显著增加(均<0.001),以至于从2016年到研究期结束,PSC肝硬化(2016年:19.4%,2018年:18.8%)超过HBV(2016年:18.4%,2018年:13.5%)、自身免疫性肝炎(2016年:11.7%,2018年:12.7%)和隐源性肝硬化(2016年:16.1%,2018年:14%),成为LT的主要指征。幸运的是,这些患者的生存率高于其他常见疾病(HR:0.53,CI:0.43‒0.66;<0.001)。
在18年的研究期间,NASH和PSC肝硬化的比例显著增加。然而,这些患者的生存率有所提高。因此,卫生组织应更加关注非传染性疾病,尤其是脂肪肝疾病和胆管炎。